Informazione Regolamentata n. 20343-30-2026	Data/Ora Inizio Diffusione 11 Novembre 2026 07:56:56	Euronext Growth Milan

Societa'	:	OTOFARMA
Utenza - referente	:	OTOFARMAESTN01 - Incarnato Bartolomucci Anna
Tipologia	:	REGEM
Data/Ora Ricezione	:	11 Novembre 2026 07:56:56
Data/Ora Inizio Diffusione	:	11 Novembre 2026 07:56:56
Oggetto	:	OTOFARMA: notice of substantial change pursuant to Article 17 of the Euronext Growth Milan Issuers' Regulation

Testo del comunicato

Vedi allegato

Teleborsa: distribution and commercial use strictly prohibited

Press release

OTOFARMA: notice of substantial change pursuant to Article 17 of the Euronext Growth Milan Issuers' Regulation

Naples, 11 November 2026 – Otofarma S.p.A., listed on Euronext Growth Milan and active in the production and marketing of hearing aids and hearing care services, announces that on 4 November it received notice from Algebris Investments (Ireland) Limited of a substantial change in its shareholding, informing the Company that it had sold, on 1 November 2026, the fund under management and, consequently, its entire shareholding in Otofarma, amounting to 333,300 shares.

On the basis of the communications received from shareholders and the information available to the Company as of today, the share capital is divided as follows:

Azionista	**Total number of shares**	**% of share capital**	**% of voting rights**
Bartolomucci Holding S.r.l.	4,000,000	67.26%	67.26%
Axon Partners Group	592,800	9.97%	9.97%
Invitalia S.p.A. (through FondoCrescial Sud)	381,600	6.42%	6.42%
Market	972,600	16.35%	16.35%
Total	5,947,000	100.00%	100.00%

Pursuant to Article 26 of the aforementioned Euronext Growth Milan Issuers' Regulations, the names of the significant Shareholders are also reported on the Company's website, on page www.otofarmaspa.com in the "Investor-Relations/Shareholding" section.

***

For the dissemination of Regulated Information, the Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, a system for the dissemination and storage of Regulated Information authorized by Consob with resolutions no. 22517 and no. 22518

Teleborsa: distribution and commercial use strictly prohibited

of 23/11/2022 pursuant to art. 113-ter, paragraph 4, letter a, of Legislative Decree no. 58/1998.

***

The Otofarma SpA Group is a leader in the design, production and marketing of customized hearing aids in the Pharmacy channel. It has built its reputation on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the aim of making access to hearing care more equitable and widespread.
A pioneer in telemedicine, Otofarma was the first company in Europe to introduce specialist teleaudiology in pharmacies: today it directly manages this service in over 4,000 affiliated pharmacies, facilitating access to diagnosis and personalisation of prostheses.
Founded by Gennaro Bartolomucci, today President and CEO, the company holds IT and instrumental patents. Its devices and services are distributed exclusively through partner pharmacies, guaranteeing a controlled and quality-oriented model.

For more information:

Otofarma S.P.A.- Investor relations
Anna Incarnato Bartolomucci
E-mail: anna.incarnato@otofarma.it
mob: +39 347 0506780

My Twin Communication - Investor Relations Advisor
otofarma@mytwincommunication.com
Mara Di Giorgio | +39 335 7737417
Federico Caretti | +39 334 3240282

SEC Newgate – Media relations
Michele Bon – michele.bon@secnewgate.it – 338 693 3868
Francesca Brambilla – francesca.brambilla@secnewgate.it – 338 627 214

Alantra – Euronext Growth Advisor
E-mail: ega@alantra.com
mob: +39 334 6267242

Fine Comunicato n.20343-30-2026	Numero di Pagine: 4